Compare AstraZeneca plc (AZN) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Costco Wholesale Corporation — how do they compare? AstraZeneca plc trades at $166.7 (market cap $253.13B), while Costco Wholesale Corporation trades at $921.4 (market cap $408.78B). The key difference: Costco Wholesale Corporation is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | COST | |
|---|---|---|
Market Cap | $253.13B | $408.78B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $1.09K |
52-Week Low | $137.44 | $849.63 |
Enterprise Value | $279.37B | $396.92B |
Dividend Yield | 1.92% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
COST trades at $926.43, up 1.11% today, with a bearish technical signal but strong fundamentals. Revenue grew to $275.24B in 2025, with net income up to $8.10B, and March 2026 sales surged 11.3% year-over-year (Costco report, April 8, 2026). Valuation ratios are elevated, with a P/E of 46.6, while analyst consensus is bullish with a $1,120 price target. Recent membership fee hikes and institutional buying support growth prospects.
Outlook remains positive due to steady revenue growth and high membership renewal rates, but risks include rich valuations and competitive pressures. The stock offers long-term value if pullbacks occur, with earnings momentum key for upside. Bearish technicals suggest near-term caution, though fundamentals underpin investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
